{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.87","value":"4.3"},{"comment":"Not eligible for this scale.","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"P-OMAQ-P"},{"categories":[{"measurements":[{"comment":"Not eligible for this scale.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"0.586","value":"4.56"}]}],"title":"P-OMAQ-C"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"The Pediatric Oral Medicine Acceptability Questionnaire (P-OMAQ) uses a 5-point numerical rate scale to measure acceptability of use of the tablet formulation with questions related to taste, smell and administration of study medication. Participants ≥ 8 years of age complete a 12-item self-report; adult parents/caregivers responsible for oversight of study drug administration for participants ages 6 months to 17 years complete a 19-item caregiver report. Each questionnaire is provided with a \"past 7 days\" recall with all items using a 5-point Numerical Rate Scale (1 to 5) with higher item-scores reflecting greater oral treatment acceptability. The overall P-OMAQ-P (pediatric self-report) and P-OMAQ-C (adult caregiver) scores for a participant in the study will be taken as the mean of all answered questions on the respective questionnaire.","dispersionType":"Standard Deviation","groups":[{"description":"Patients aged 8 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901)"},{"description":"The adult caregiver of Pediatric patients aged 8 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Adult Caregiver Mirdametinib (PD-0325901)"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set eligible for the instrument at baseline","reportingStatus":"POSTED","timeFrame":"Completed only once through study completion","title":"Acceptability of the Dispersible Tablet Formulation as Measured by the Pediatric Oral Medicine Acceptability Questionnaire (P-OMAQ)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"units on a scale"}